Welcome to the e-CCO Library!

P748: Pharmacokinetics, relative bioavailability, and dose proportionality of a tablet formulation of the sphingosine 1-phosphate-1 receptor modulator VTX002 (formerly OPL-002)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gregg, R.(1);Yun, C.(1)*;Naik, S.(1);Huyghe, M.(2);Harris, J.(2);Mohan, R.(1);Nuss, J.(1);Sandborn, W.J.(1);
Created: Friday, 14 July 2023, 11:12 AM
P748: Retrospective study on incidence rates of NAFLD and advanced liver fibrosis in Crohn's disease and ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Domislovic*1, I. Knezevic Stromar1, M. Premuzic1, D. Vranesic Bender2,3, M. Matasin4, A. Milinkovic4, I. Mikolasevic5,6, Z. Krznaric1,2,4

Created: Friday, 22 February 2019, 9:41 AM
P749 Epidemiological and clinical characterisation of inflammatory bowel disease (IBD) in Latin America and the Caribbean: The EPI-LATAM IBD study from the Pan American Crohn’s colitis organisation
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.K. Yamamoto-Furusho1, N.N. Parra-Holguín2, E. Grupo-Colombiano3, F. Bosques-Padilla4, G. Veitia-Velásquez5, E. Torres6, F. Piñol-Jiménez7, S. Bautista8, A. Frías-Santana9, K. Villa-Ovalles8, G. Otoya-Moreno10, B. Iadé-Vergara11, EPILATAM-Study Group

Created: Thursday, 30 January 2020, 10:12 AM
P749: A comparative analysis of low bioavailability steroids in inducing clinical response and remission in ulcerative colitis: Budesonide MMX as the safest option
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Scrivo, E. Giuffrida, V. Calvaruso, M. Cappello*

Created: Thursday, 21 February 2019, 9:14 AM
P749: Crohn's disease stricture response and resolution with adalimumab therapy demonstrated with intestinal ultrasound. The STRIDENT randomised trial.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lovett, G.(1,2)*;Schulberg, J.D.(1,2);Hamilton, A.L.(1,2);Wright, E.K.(1,2);Sutherland, T.R.(2,3);Kamm, M.A.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P749: Early environmental and lifestyle factors are associated with developing inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. van der Sloot*1,2, R. Weersma1, B. Alizadeh2, G. Dijkstra1

Created: Friday, 22 February 2019, 9:41 AM
P749: Impact of psycho-social variables on the activity of inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sarid O.1, Slomin-Nevo V.1, Schwartz D.2, Friger M.3, Sergienko R.3, Chernin E.3, Vardi H.3, Greenberg D.4, Odes S.*5

Created: Wednesday, 20 February 2019, 10:36 AM
P750 Prevalence and characteristics of incidentally diagnosed inflammatory bowel disease during screening colonoscopy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y.M. Han1, J. Lee1, J.P. Im2, J.S. Kim1

Created: Thursday, 30 January 2020, 10:12 AM
P750: Association between the use of antihypertensive agents and disease severity in patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Mantaka*1, E. Tsoukali2, M. Fragaki3, K. Karmiris3, N. Viazis2, G. Mantzaris2, I. Koutroubakis1

Created: Friday, 22 February 2019, 9:41 AM
P750: Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National U.S. Cohort of U.S. Military Veterans with Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hou, J.K.(1)*;Pham, C.(2);Sansgiry, S.(3);Modi, V.(2);Waljee, A.K.(4);
Created: Friday, 14 July 2023, 11:12 AM
P750: Predictors of quick remission after cyclosporine A therapy in Paediatric ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Osiecki*, M. Dadalski, J. Kierkus

Created: Thursday, 21 February 2019, 9:14 AM
P750: Prevalence and risk factors of cholelithiasis in patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sturdik I., Krajcovicova A., Leskova Z., Decka R., Cernotova V., Koller T., Huorka M., Hlavaty T.

Created: Wednesday, 20 February 2019, 10:36 AM
P751 Prevalence and risk factors of non-alcoholic fatty liver disease in inflammatory bowel diseases
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Hoffmann1, V. Jung1, R. Behnisch2, A. Gauss1

Created: Thursday, 30 January 2020, 10:12 AM
P751: Crohn's Disease Exclusion Diet: A single centre real-life experience.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lababidi, N.E.(1)*;Pavel, F.(1);
Created: Friday, 14 July 2023, 11:12 AM
P751: Perianal lesions in Crohn's disease: analysis of Epimad registry from 2007 to 2012
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Wils*1, A. Leroyer2, M. Fumery3, A. Fernandez Nistal4, D. Bojic4, R. D′Ambrosio4, H. Sarter2, G. Savoye5, C. Gower-Rousseau2, B. Pariente6

Created: Friday, 22 February 2019, 9:41 AM
P751: Time course of the incidence and magnitude of anti-drug antibodies to adalimumab and ABP 501 among patients on concomitant immunomodulatory therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Mytych*, J. Miller, M. Starcevic Manning, I. Wala, H. Wang, N. Zhang, E. Krishnan, A. Kaliyaperumal

Created: Thursday, 21 February 2019, 9:14 AM
P751: Trends in incidence of inflammatory bowel disease in northwest Greece
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Skamnelos A.*1, Katsanos K.1, Malakos Z.1, Kolios S.2, Mitselos I.1, Politis D.1, Mpalomenos D.1, Kavadias A.1, Tzampouras N.1, Mpaltagiannis G.1, Tsianos E.1, Christodoulou D.1

Created: Wednesday, 20 February 2019, 10:36 AM
P752 A nationwide survey of chronic enteropathy associated with SLCO2A1 gene in Japan
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Umeno1, Y. Fuyuno1, T. Torisu1, A. Hirano1, M. Esaki2, S. Yanai3, N. Ohmiya4, T. Hisamatsu5, K. Watanabe6, N. Hosoe7, H. Ogata7, F. Hirai8, T. Hisabe9, T. Matsui9, T. Yao10, T. Kitazono1, T. Matsumoto3, CEAS Study Group

Created: Thursday, 30 January 2020, 10:12 AM
P752: Increased risk of hip fracture in patients with inflammatory bowel disease: a national registry-based nested case–control study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Bartko*1, B. Reichardt2, R. Kocijan1, K. Klaushofer1, J. Zwerina1, M. Behanova1

Created: Friday, 22 February 2019, 9:41 AM
P752: Oral once daily budesonide granules rapidly induce clinical remission in Lymphocytic Colitis: A double-blind, double-dummy, multi-centre, randomised trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Miehlke1*, D. Aust2, E. Mihaly3, P. Armerding4, G. Böhm5, O. Bonderup6, F. Fernández-Bañares7, J. Kupcinskas8, L.K. Munck9, K.-U. Rehbehn10, T. Nacak11, R. Greinwald11, A. Münch12

Created: Thursday, 21 February 2019, 9:14 AM